Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Krasner

Showing results (81-90 of 110) with videos related to

Pageof 11
Sort By:
Gynecologic Oncology|October 7, 2009
A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic OncologyDavid Scott Miller, John A Blessing, Richard D Drake, et al.
British Medical Journal (Clinical Research Ed.)|October 6, 1984
Is there a place in the United Kingdom for intensive antacid treatment for chronic peptic ulceration?R Faizallah, H A De Haan, N Krasner, et al.
British Medical Journal|September 25, 1976
Histocompatibility antigens, autoantibodies, and immunoglobulins in alcoholic liver diseaseR J Bailey, N Krasner, A L Eddleston, et al.
Journal of Photochemistry and Photobiology. B, Biology|February 15, 2000
Photodynamic therapy using 5-aminolaevulinic acid for oesophageal adenocarcinoma associated with Barrett's metaplasiaW C Tan, C Fulljames, N Stone, et al.
Gynecologic Oncology|December 8, 2004
A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancerAnna Berkenblit, Michael V Seiden, Ursula A Matulonis, et al.
The Oncologist|January 31, 2023
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian CancerRichard T Penson, Allison J Ambrosio, Christin A Whalen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology GroupDavid S Miller, John A Blessing, Carolyn N Krasner, et al.
British Journal of Cancer|November 15, 2007
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimensC N Krasner, D S McMeekin, S Chan, et al.
Gynecologic Oncology|March 29, 2006
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancerU A Matulonis, S Campos, L Duska, et al.
Gynecologic Oncology|June 30, 2006
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimenU A Matulonis, S Campos, C N Krasner, et al.
Pageof 11

Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
Gynecologic Oncology|October 7, 2009
A phase II evaluation of pemetrexed (Alimta, LY231514, IND #40061) in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic OncologyDavid Scott Miller, John A Blessing, Richard D Drake, et al.
British Medical Journal (Clinical Research Ed.)|October 6, 1984
Is there a place in the United Kingdom for intensive antacid treatment for chronic peptic ulceration?R Faizallah, H A De Haan, N Krasner, et al.
British Medical Journal|September 25, 1976
Histocompatibility antigens, autoantibodies, and immunoglobulins in alcoholic liver diseaseR J Bailey, N Krasner, A L Eddleston, et al.
Journal of Photochemistry and Photobiology. B, Biology|February 15, 2000
Photodynamic therapy using 5-aminolaevulinic acid for oesophageal adenocarcinoma associated with Barrett's metaplasiaW C Tan, C Fulljames, N Stone, et al.
Gynecologic Oncology|December 8, 2004
A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancerAnna Berkenblit, Michael V Seiden, Ursula A Matulonis, et al.
The Oncologist|January 31, 2023
Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian CancerRichard T Penson, Allison J Ambrosio, Christin A Whalen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2009
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology GroupDavid S Miller, John A Blessing, Carolyn N Krasner, et al.
British Journal of Cancer|November 15, 2007
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimensC N Krasner, D S McMeekin, S Chan, et al.
Gynecologic Oncology|March 29, 2006
Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancerU A Matulonis, S Campos, L Duska, et al.
Gynecologic Oncology|June 30, 2006
Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimenU A Matulonis, S Campos, C N Krasner, et al.
Pageof 11